Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex Campus, Brighton, BN1 9RY, UK.
Department of Rheumatology, Brighton & Sussex University Hospitals, Brighton, UK.
Mol Psychiatry. 2021 Sep;26(9):5150-5160. doi: 10.1038/s41380-020-0790-9. Epub 2020 May 26.
A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD). Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the "inflammatory theory" of depression. Heightened amygdala reactivity (particularly to negatively valanced stimuli) is a consistent finding within MDD; can predict treatment efficacy and reverses following successful treatment. However, whether IFN-α and anti-TNF enhance/attenuate depressive symptoms through modulation of amygdala emotional reactivity is unknown. Utilizing a prospective study design, we recruited 30 patients (mean 48.0 ± 10.5 years, 21 male) initiating IFN-α treatment for Hepatitis-C and 30 (mean 50.4 ± 15.7 years, 10 male) anti-TNF therapy for inflammatory arthritis. All completed an emotional face-processing task during fMRI and blood sampling before and after their first IFN-α (4-h) or anti-TNF (24-h) injection and follow-up psychiatric assessments for 3 months of treatment. IFN-α significantly increased depression symptoms (Hamilton Depression Rating Scale HAM-D) at 4 weeks (p < 0.001) but not 4-h after first dose (p > 0.1). Conversely, anti-TNF significantly improved depressive symptoms (Hospital Anxiety and Depression Rating Scale HADS) at both 24-h (P = 0.015) and 12 weeks (p = 0.018). In support of our a-priori hypothesis, both IFN-α and anti-TNF significantly modulated amygdala reactivity with IFN-α acutely enhancing right amygdala responses to sad (compared with neutral) faces (p = 0.032) and anti-TNF conversely decreasing right amygdala reactivity (across emotional valence) (p = 0.033). Furthermore, these changes predicted IFN-induced increases in HAM-D 4 weeks later (R = 0.17, p = 0.022) and anti-TNF-associated decreases in HADS at 24-h (R = 0.23, p = 0.01) suggesting that actions of systemic inflammation on amygdala emotional reactivity play a mechanistic role in inflammation-associated depressive symptoms.
三分之一接受干扰素-α(IFN-α)治疗丙型肝炎的患者会出现重度抑郁症(MDD)。相反,抗肿瘤坏死因子(TNF)疗法可改善抑郁症,为抑郁症的“炎症理论”提供了关键的实证支持。在 MDD 中,杏仁核反应性增强(特别是对负性效价刺激)是一致的发现;可以预测治疗效果,并在成功治疗后逆转。然而,IFN-α 和抗 TNF 是否通过调节杏仁核的情绪反应来增强/减轻抑郁症状尚不清楚。利用前瞻性研究设计,我们招募了 30 名(平均年龄 48.0±10.5 岁,21 名男性)开始接受 IFN-α 治疗丙型肝炎的患者和 30 名(平均年龄 50.4±15.7 岁,10 名男性)接受抗 TNF 治疗炎症性关节炎的患者。所有患者在接受第一次 IFN-α(4 小时)或抗 TNF(24 小时)注射前和注射后完成 fMRI 和血液采样,并在治疗的 3 个月内进行后续精神病学评估。IFN-α 在 4 周时显著增加了抑郁症状(汉密尔顿抑郁评定量表 HAM-D)(p<0.001),但在首次剂量后 4 小时内没有增加(p>0.1)。相反,抗 TNF 在 24 小时(P=0.015)和 12 周时(p=0.018)均显著改善了抑郁症状(医院焦虑和抑郁量表 HADS)。支持我们的假设,IFN-α 和抗 TNF 都显著调节了杏仁核反应性,IFN-α 急性增强了右侧杏仁核对悲伤(与中性)面孔的反应(与中性相比)(p=0.032),而抗 TNF 则相反降低了右侧杏仁核的反应性(跨情绪效价)(p=0.033)。此外,这些变化预测了 IFN 诱导的 HAM-D 在 4 周后增加(R=0.17,p=0.022)和抗 TNF 相关的 24 小时内 HADS 降低(R=0.23,p=0.01),表明全身炎症对杏仁核情绪反应的作用在炎症相关的抑郁症状中具有机制作用。